These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

280 related items for PubMed ID: 27405747

  • 41. IL-10 gene polymorphism c.-592C>A increases HPV infection susceptibility and influences IL-10 levels in HPV infected women.
    Berti FCB, Pereira APL, Trugilo KP, Cebinelli GCM, Silva LFDRS, Lozovoy MAB, Simão ANC, Watanabe MAE, de Oliveira KB.
    Infect Genet Evol; 2017 Sep; 53():128-134. PubMed ID: 28552689
    [Abstract] [Full Text] [Related]

  • 42. Association of the IL-10 gene rs1800872 (-592 C>A) polymorphism with breast cancer in a Mexican population.
    Patricia Gallegos-Arreola M, Zúñiga González GM, Figuera LE, Puebla Pérez AM, Delgado Saucedo JI.
    J BUON; 2019 Sep; 24(6):2369-2376. PubMed ID: 31983108
    [Abstract] [Full Text] [Related]

  • 43. Interleukin-10 gene promoter polymorphism in Polish rheumatoid arthritis patients.
    Paradowska-Gorycka A, Trefler J, Maciejewska-Stelmach J, Łacki JK.
    Int J Immunogenet; 2010 Aug; 37(4):225-31. PubMed ID: 20477882
    [Abstract] [Full Text] [Related]

  • 44. The Applicability of the International Staging System in Chinese Patients with Multiple Myeloma Receiving Bortezomib or Thalidomide-Based Regimens as Induction Therapy: A Multicenter Analysis.
    Lu J, Lu J, Liu A, Fu W, Du J, Huang X, Chen W, Hou J.
    Biomed Res Int; 2015 Aug; 2015():856704. PubMed ID: 26640799
    [Abstract] [Full Text] [Related]

  • 45.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 46. Community-Based Phase IIIB Trial of Three UPFRONT Bortezomib-Based Myeloma Regimens.
    Niesvizky R, Flinn IW, Rifkin R, Gabrail N, Charu V, Clowney B, Essell J, Gaffar Y, Warr T, Neuwirth R, Zhu Y, Elliott J, Esseltine DL, Niculescu L, Reeves J.
    J Clin Oncol; 2015 Nov 20; 33(33):3921-9. PubMed ID: 26056177
    [Abstract] [Full Text] [Related]

  • 47.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 48.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 49. Salvage therapy in first relapse: a retrospective study in a large patient population with multiple myeloma.
    Offidani M, Corvatta L, Bringhen S, Gentili S, Troia R, Maracci L, Larocca A, Gay F, Leoni P, Boccadoro M.
    Eur J Haematol; 2017 Mar 20; 98(3):289-295. PubMed ID: 27893171
    [Abstract] [Full Text] [Related]

  • 50. Association of IFNAR2 and IL10RB genes in chronic hepatitis B virus infection.
    Romporn S, Hirankarn N, Tangkijvanich P, Kimkong I.
    Tissue Antigens; 2013 Jul 20; 82(1):21-5. PubMed ID: 23745570
    [Abstract] [Full Text] [Related]

  • 51.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 52.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 53. Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients: A retrospective case-matched study.
    Morabito F, Bringhen S, Larocca A, Wijermans P, Victoria Mateos M, Gimsing P, Mazzone C, Gottardi D, Omedè P, Zweegman S, José Lahuerta J, Zambello R, Musto P, Magarotto V, Schaafsma M, Oriol A, Juliusson G, Cerrato C, Catalano L, Gentile M, Isabel Turel A, Marina Liberati A, Cavalli M, Rossi D, Passera R, Rosso S, Beksac M, Cavo M, Waage A, San Miguel J, Boccadoro M, Sonneveld P, Palumbo A, Offidani M.
    Am J Hematol; 2014 Apr 20; 89(4):355-62. PubMed ID: 24273190
    [Abstract] [Full Text] [Related]

  • 54. Impact of Genetic Polymorphisms in NF-ĸB2 and TRAF3 Genes on Response to Bortezomib-Based Therapy in Multiple Myeloma Patients.
    Sood N, Hamide A, Dubashi B, Nisha Y, Mathaiyan J, Munirajan AK, Ganesn P, Kayal S.
    Asian Pac J Cancer Prev; 2024 Mar 01; 25(3):829-837. PubMed ID: 38546066
    [Abstract] [Full Text] [Related]

  • 55. Thalidomide consolidation improves progression-free survival in myeloma with normal but not up-regulated expression of fibroblast growth factor receptor 3: analysis from the Australasian Leukaemia and Lymphoma Group MM6 clinical trial.
    Ho PJ, Brown RD, Spencer A, Jeffels M, Daniher D, Gibson J, Joshua DE.
    Leuk Lymphoma; 2012 Sep 01; 53(9):1728-34. PubMed ID: 22329352
    [Abstract] [Full Text] [Related]

  • 56. LDH is an adverse prognostic factor independent of ISS in transplant-eligible myeloma patients receiving bortezomib-based induction regimens.
    Chim CS, Sim J, Tam S, Tse E, Lie AK, Kwong YL.
    Eur J Haematol; 2015 Apr 01; 94(4):330-5. PubMed ID: 25135740
    [Abstract] [Full Text] [Related]

  • 57.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 58. CyclinD1 and interleukin-1 receptor antagonist polymorphisms are associated with prognosis in neoadjuvant-treated gastric carcinoma.
    Stocker G, Ott K, Henningsen N, Becker K, Hapfelmeier A, Lordick F, Hois S, Plaschke S, Höfler H, Keller G.
    Eur J Cancer; 2009 Dec 01; 45(18):3326-35. PubMed ID: 19822419
    [Abstract] [Full Text] [Related]

  • 59. A comparison of salvage infusional chemotherapy regimens for recurrent/refractory multiple myeloma.
    Griffin PT, Ho VQ, Fulp W, Nishihori T, Shain KH, Alsina M, Baz RC.
    Cancer; 2015 Oct 15; 121(20):3622-30. PubMed ID: 26149422
    [Abstract] [Full Text] [Related]

  • 60. IDO2 rs10109853 polymorphism affects the susceptibility to multiple myeloma.
    Kasamatsu T, Hashimoto N, Sakaya N, Awata-Shiraiwa M, Ishihara R, Murakami Y, Masuda Y, Gotoh N, Nagai K, Oda T, Yokohama A, Saitoh T, Handa H, Tsukamoto N, Hayashi K, Murakami H.
    Clin Exp Med; 2021 May 15; 21(2):323-329. PubMed ID: 33709342
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.